Compare Stocks → Here’s how to start a “Weekend Side Hustle” from your sofa (From DTI) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ALLKNASDAQ:EWTXNASDAQ:ICPTNASDAQ:NKTR Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLKAllakos$1.06-0.9%$1.28$1.00▼$5.64$94.03M0.82425,446 shs279,226 shsEWTXEdgewise Therapeutics$15.08-1.0%$16.96$5.12▼$20.69$1.42B0.14499,311 shs378,814 shsICPTIntercept Pharmaceuticals$19.00$18.88$8.82▼$21.86$794.77M0.881.36 million shsN/ANKTRNektar Therapeutics$1.36+9.7%$0.97$0.41▼$1.75$227.69M0.93.72 million shs1.97 million shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLKAllakos-0.93%-1.85%-21.48%-10.17%-76.81%EWTXEdgewise Therapeutics-0.98%-8.50%-7.20%-2.46%+97.90%ICPTIntercept Pharmaceuticals0.00%0.00%0.00%0.00%-0.21%NKTRNektar Therapeutics+9.68%-13.38%+48.88%+166.67%+56.32%At first glance, this chart looks like nonsense… (Ad)We can isolate the most bullish dates to buy Netflix each and every year… That’s why one former hedge fund manager calls these dates… “Hotspot Dates”But if you want the stock with “Hotspot Dates” hitting NEXT WEEK…MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALLKAllakos4.1144 of 5 stars3.13.00.04.70.63.31.3EWTXEdgewise Therapeutics1.5724 of 5 stars3.51.00.00.02.03.30.0ICPTIntercept Pharmaceuticals0.322 of 5 stars1.00.00.03.90.01.70.6NKTRNektar Therapeutics4.0251 of 5 stars3.05.00.04.20.92.50.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALLKAllakos2.20Hold$1.8372.96% UpsideEWTXEdgewise Therapeutics3.00Buy$31.20106.90% UpsideICPTIntercept Pharmaceuticals2.00Hold$19.864.51% UpsideNKTRNektar Therapeutics2.00Hold$3.50157.35% UpsideCurrent Analyst RatingsLatest ALLK, NKTR, ICPT, and EWTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/22/2024EWTXEdgewise TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$28.00 ➝ $32.004/17/2024EWTXEdgewise TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.004/16/2024EWTXEdgewise TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$26.003/7/2024EWTXEdgewise TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$48.003/6/2024NKTRNektar TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold ➝ Hold$0.50 ➝ $1.003/5/2024NKTRNektar TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALLKAllakosN/AN/AN/AN/A$1.93 per shareN/AEWTXEdgewise TherapeuticsN/AN/AN/AN/A$4.53 per shareN/AICPTIntercept Pharmaceuticals$285.71M2.78N/AN/A$1.72 per share11.05NKTRNektar Therapeutics$90.12M2.77N/AN/A$0.69 per share1.97Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALLKAllakos-$185.70M-$2.13N/AN/AN/AN/A-80.23%-62.03%5/14/2024 (Estimated)EWTXEdgewise Therapeutics-$100.16M-$1.58N/AN/AN/AN/A-32.06%-30.16%5/9/2024 (Estimated)ICPTIntercept Pharmaceuticals$221.82M-$1.48N/A9.84N/A-19.39%-77.48%-11.99%N/ANKTRNektar Therapeutics-$276.06M-$1.46N/AN/AN/A-306.31%-96.80%-37.17%5/14/2024 (Estimated)Latest ALLK, NKTR, ICPT, and EWTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/14/2024Q4 2023ALLKAllakos-$0.53-$0.71-$0.18-$0.71N/AN/A3/4/202412/31/2023NKTRNektar Therapeutics-$0.21-$0.22-$0.01-$0.22$17.09 million$23.89 million 2/22/2024Q4 2023EWTXEdgewise Therapeutics-$0.44-$0.47-$0.03-$0.47N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALLKAllakosN/AN/AN/AN/AN/AEWTXEdgewise TherapeuticsN/AN/AN/AN/AN/AICPTIntercept PharmaceuticalsN/AN/AN/AN/AN/ANKTRNektar TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALLKAllakosN/A4.924.92EWTXEdgewise TherapeuticsN/A19.5019.50ICPTIntercept Pharmaceuticals3.124.222.52NKTRNektar TherapeuticsN/A6.456.14OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALLKAllakos84.64%EWTXEdgewise TherapeuticsN/AICPTIntercept Pharmaceuticals83.81%NKTRNektar Therapeutics75.88%Insider OwnershipCompanyInsider OwnershipALLKAllakos28.07%EWTXEdgewise Therapeutics31.95%ICPTIntercept Pharmaceuticals6.20%NKTRNektar Therapeutics3.07%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableALLKAllakos13187.87 million63.21 millionOptionableEWTXEdgewise Therapeutics8893.11 million63.36 millionOptionableICPTIntercept Pharmaceuticals34141.83 million39.19 millionOptionableNKTRNektar Therapeutics137183.62 million177.98 millionOptionableALLK, NKTR, ICPT, and EWTX HeadlinesSourceHeadlineNatural Killer (NK) Cell Therapy Pipeline Research Report 2024: Comprehensive Insights About 100+ Companies and 185+ Pipeline Drugsfinance.yahoo.com - April 20 at 8:58 AMNektar regains Nasdaq compliance with bid priceinvesting.com - April 20 at 12:52 AMNektar Therapeutics (NASDAQ:NKTR) Stock Price Passes Above Two Hundred Day Moving Average of $0.65americanbankingnews.com - April 16 at 2:34 AMNektar Therapeutics Sees Something In The Data And Puts Its Drug To The Testseekingalpha.com - April 10 at 1:44 AMUS open: Stocks trade higher, Dow reverses yesterday's lossessharecast.com - April 4 at 3:34 PMNektar (NKTR) Up 7.5% Since Last Earnings Report: Can It Continue?zacks.com - April 3 at 12:31 PMNektar Therapeutics (NASDAQ:NKTR) Sees Large Growth in Short Interestmarketbeat.com - April 1 at 7:56 PMCult 70s proggers’ absorbing sixth album presented at its fullest.loudersound.com - March 30 at 8:47 AM“A fascinating listen that sometimes sounds like a missing 10cc album plus a little Be Box Deluxe”: Nektar’s Recycled 5CD setyahoo.com - March 29 at 5:45 PMNektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conferenceprnewswire.com - March 22 at 2:00 PMUS open: Stocks lower as inflation data weighs on marketssharecast.com - March 15 at 1:38 PMNektar (NKTR) Begins Phase IIb Study Rezpeg in Alopecia Areatazacks.com - March 6 at 1:35 PMNektar Therapeutics (NASDAQ:NKTR) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - March 5 at 2:06 PMNektar (NKTR) Q4 Loss Wider Than Expected, Revenue Beatzacks.com - March 5 at 11:11 AMQ4 2023 Nektar Therapeutics Earnings Callfinance.yahoo.com - March 5 at 9:06 AMNektar Therapeutics Announces Initiation of Phase 2b Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areataprnewswire.com - March 5 at 9:00 AMNektar Therapeutics (NKTR) Reports Q4 Loss, Tops Revenue Estimateszacks.com - March 4 at 6:31 PMNektar Therapeutics Q4 Loss decreases, but misses estimatesmarkets.businessinsider.com - March 4 at 6:05 PMNektar Therapeutics (NKTR) Reports Fiscal Year-End and Q4 2023 Resultsfinance.yahoo.com - March 4 at 6:05 PMNektar Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Resultsprnewswire.com - March 4 at 4:15 PMNektar Therapeutics Announces $30 Mln Private Placement Financing With TCGX; Stock Up In Premarketmarkets.businessinsider.com - March 4 at 1:05 PMNektar Therapeutics Announces $30 Million Private Placement Financing with TCGXprnewswire.com - March 4 at 8:30 AMNektar Therapeutics earnings: here's what Wall Street expectsmarkets.businessinsider.com - March 3 at 10:01 AMNektar Therapeutics Earnings Previewbenzinga.com - March 1 at 11:43 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAllakosNASDAQ:ALLKAllakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.Edgewise TherapeuticsNASDAQ:EWTXEdgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.Intercept PharmaceuticalsNASDAQ:ICPTIntercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis and NASH; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in Morristown, New Jersey. As of November 8, 2023, Intercept Pharmaceuticals, Inc. operates as a subsidiary of Alfasigma S.p.A..Nektar TherapeuticsNASDAQ:NKTRNektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer squamous cell carcinoma and colorectal cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.